Bliss GVS Pharma Bags EU GMP Certification for 2 Units

Bliss GVS Pharma, a small-cap pharmaceutical company, witnessed a 5% surge in its stock price on Monday, reaching an intraday high of ₹138.20. The rise comes as the company announced receiving a Good Manufacturing Practice (GMP) certification from the European regulatory authority for its manufacturing facilities.

European GMP Certification Achievement

On Saturday, Bliss GVS Pharma confirmed that two of its manufacturing units in Palghar, Maharashtra, achieved GMP compliance. These facilities, located at Plot No. 11, Dewan Udyog Nagar, and Survey No. 43-44, Vevoor Village, were inspected by the National Agency for Medicines and Medical Devices of Romania (NAMMDR) on November 30 and December 1, 2023. The certification demonstrates that the company’s production processes adhere to stringent European Union (EU) quality and safety standards.

This accomplishment is a major step for Bliss GVS Pharma, as GMP certification is a prerequisite for entering and expanding operations in regulated markets like Europe. It ensures that the company meets international manufacturing benchmarks, enhancing its reputation globally.

Impact on Stock Performance and Future Prospects

The news had an immediate positive impact on Bliss GVS Pharma’s stock, which gained up to 5% in intraday trading and made an intraday high of Rs.138.36 per share. The stock currently trades at Rs.132.62 per share losing most of its morning session gains. Analysts believe this milestone strengthens the company’s position in the global pharmaceutical market and opens doors for new partnerships and product launches in Europe. As GMP certification is a critical requirement for entering regulated markets, this development is expected to enhance the company’s revenue streams and reinforce investor confidence. 

Conclusion: Bliss GVS Pharma’s achievement of European GMP certification is a testament to its commitment to maintaining high-quality manufacturing practices. The positive market reaction reflects investor optimism about the company’s future growth prospects in international markets.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.